5 Most Promising Healthcare Stocks According to Analysts

3. BeiGene, Ltd. (NASDAQ:BGNE)

Average Analyst Price Target Upside: 46.7%

Average Analyst Price Target: $267.67

BeiGene, Ltd. (NASDAQ:BGNE) is a commercial-stage biopharmaceutical company that produces oncology-related medication.

On November 21, BeiGene, Ltd. (NASDAQ:BGNE) announced that it agreed to pay over $1 billion to get an exclusive global license for a cancer candidate by Ensem Therapeutics. The global R&D head, Lai Wang, commented that the candidate will strengthen the company’s early development pipeline for breast cancer and other solid tumors.

On November 21, BeiGene, Ltd. (NASDAQ:BGNE) reported that it received the FDA’s orphan drug designation for its sonrotoclax drug candidate.

On November 17, BeiGene, Ltd. (NASDAQ:BGNE) announced that its BRUKINSA (zanubrutinib), in combination with obinutuzumab, received marketing authorization from the European Commission (EC), making it the only and first-ever BTK inhibitor approved for follicular lymphoma in the EU.

Follow Beigene Ltd. (NASDAQ:BGNE)